Status and phase
Conditions
Treatments
About
The purpose of the study is to demonstrate the efficacy and safety of certolizumab pegol in the treatment of moderate to severe chronic plaque psoriasis in study participants aged 6 to 11 and 12 to 17 years.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Study participant must have a diagnosis of moderate to severe plaque psoriasis (PSO) for ≥3 months and:
Body Surface Area (BSA) affected by psoriasis ≥10 %
Physician's Global Assessment (PGA) score ≥3 (on a scale from 0 to 4)
Psoriasis Area and Severity Index (PASI) score is ≥12 or
PASI score is ≥10 and <12 with at least one of the following:
Study participant must be a candidate for systemic psoriasis therapy and/or phototherapy and/or photochemotherapy
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
150 participants in 3 patient groups, including a placebo group
Loading...
Central trial contact
UCB Cares
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal